Accueil   Diary - News   All news MaaT Pharma Announces Publication of Results from Completed Phase 1/2 ODYSSEE Clinical Trial

MaaT Pharma Announces Publication of Results from Completed Phase 1/2 ODYSSEE Clinical Trial

 

MaaT Pharma Announces Publication of Results from Completed Phase 1/2 ODYSSEE Clinical Trial in Nature Communications

 

  • The trial of the autologous microbial therapy, MaaT011, met its primary endpoints through demonstration of restored gut microbiota balance and diversity as well as reduction of antibiotic resistance gene carriage
  • MaaT011 was safe after induction chemotherapy in acute myeloid leukemia patients
  • MaaT011 formed the basis of the company’s full ecosystem therapeutic approach that was continued with product candidates MaaT013 (in acute graft-vs-host disease) and MaaT033 (in acute myeloid leukemia)

 

Lyon, France, May 25, 2021 – MaaT Pharma announced today that final results from its Phase 1/2 ODYSSEE clinical trial have been published in the journal, Nature Communications. The data demonstrated that the company’s initial product candidate, MaaT011, an autologous fecal microbiota transfer treatment, was safe and effective in fully restoring the gut microbiota in the 20 per-protocol analysis set of acute myeloid leukemia (AML) patients. In addition, the MaaT011 treatment showed short- and long-term signs of positive clinical outcomes including the reduction of both intestinal inflammation and gut carriage of antibiotic resistance genes. Topline data from the study had been previously presented in a poster presentation at the 60th American Society of Hematology (ASH) Annual Meeting in December 2018.

 

Read the press release